Donald L. Morton

50.7k total citations · 8 hit papers
448 papers, 33.4k citations indexed

About

Donald L. Morton is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Donald L. Morton has authored 448 papers receiving a total of 33.4k indexed citations (citations by other indexed papers that have themselves been cited), including 251 papers in Oncology, 193 papers in Immunology and 141 papers in Molecular Biology. Recurrent topics in Donald L. Morton's work include Immunotherapy and Immune Responses (160 papers), Cutaneous Melanoma Detection and Management (127 papers) and Cancer Immunotherapy and Biomarkers (63 papers). Donald L. Morton is often cited by papers focused on Immunotherapy and Immune Responses (160 papers), Cutaneous Melanoma Detection and Management (127 papers) and Cancer Immunotherapy and Biomarkers (63 papers). Donald L. Morton collaborates with scholars based in United States, Australia and India. Donald L. Morton's co-authors include Frederick R. Eilber, Alistair J. Cochran, John F. Thompson, Richard Essner, Dave S.�B. Hoon, Robert M. Elashoff, Reiko F. Irie, Jeffrey E. Gershenwald, Kelly M. McMasters and Charles M. Balch and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Donald L. Morton

441 papers receiving 31.7k citations

Hit Papers

Final Version of 2009 AJC... 1970 2026 1988 2007 2009 1992 2001 2006 2014 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Final Version of 2009 AJCC Melanoma Staging and Classification
    2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
  2. Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma
    1992 3.3k citations Donald L. Morton profile →
  3. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
    2001 2.0k citations Charles M. Balch, Antônio C. Buzaid et al. Journal of Clinical Oncology profile →
  4. Sentinel-Node Biopsy or Nodal Observation in Melanoma
    2006 1.2k citations Donald L. Morton, John F. Thompson et al. profile →
  5. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
    2014 943 citations Donald L. Morton, John F. Thompson et al. profile →
  6. Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma
    1999 579 citations Donald L. Morton, John F. Thompson et al. Annals of Surgery profile →
  7. Impaired immunologic reactivity and recurrence following cancer surgery
    1970 550 citations Donald L. Morton et al. Cancer profile →
  8. Sentinel Node Biopsy for Early-Stage Melanoma
    2005 504 citations Donald L. Morton, Alistair J. Cochran et al. Annals of Surgery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donald L. Morton United States 86 22.7k 10.4k 8.8k 6.8k 4.0k 448 33.4k
Martín C. Mihm United States 94 20.4k 0.9× 9.2k 0.9× 8.2k 0.9× 5.4k 0.8× 2.3k 0.6× 456 34.5k
Merrick I. Ross United States 90 24.6k 1.1× 8.2k 0.8× 5.4k 0.6× 7.3k 1.1× 9.4k 2.4× 425 34.7k
Alexander M.M. Eggermont Netherlands 72 18.5k 0.8× 9.4k 0.9× 6.7k 0.8× 3.5k 0.5× 2.7k 0.7× 389 25.8k
John M. Kirkwood United States 104 31.3k 1.4× 17.9k 1.7× 18.8k 2.1× 4.8k 0.7× 3.9k 1.0× 687 46.4k
Claus Garbe Germany 93 21.3k 0.9× 15.0k 1.5× 7.0k 0.8× 6.3k 0.9× 2.2k 0.6× 750 34.4k
Richard A. Scolyer Australia 84 21.3k 0.9× 13.3k 1.3× 6.6k 0.8× 4.1k 0.6× 4.3k 1.1× 707 30.6k
Dirk Schadendorf Germany 101 27.6k 1.2× 21.3k 2.1× 15.5k 1.7× 3.5k 0.5× 4.2k 1.1× 982 46.5k
Kelly M. McMasters United States 69 15.0k 0.7× 6.3k 0.6× 3.4k 0.4× 5.1k 0.7× 4.5k 1.1× 434 23.5k
Jeffrey E. Gershenwald United States 72 19.6k 0.9× 9.8k 1.0× 5.0k 0.6× 5.7k 0.8× 2.6k 0.7× 283 25.5k
Daniel D. Von Hoff United States 91 23.6k 1.0× 19.7k 1.9× 2.8k 0.3× 4.1k 0.6× 8.3k 2.1× 821 44.9k

Countries citing papers authored by Donald L. Morton

Since Specialization
Citations

This map shows the geographic impact of Donald L. Morton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald L. Morton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald L. Morton more than expected).

Fields of papers citing papers by Donald L. Morton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald L. Morton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald L. Morton. The network helps show where Donald L. Morton may publish in the future.

Co-authorship network of co-authors of Donald L. Morton

This figure shows the co-authorship network connecting the top 25 collaborators of Donald L. Morton. A scholar is included among the top collaborators of Donald L. Morton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald L. Morton. Donald L. Morton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marzese, Diego M., Richard A. Scolyer, Sharon K. Huang, et al.. (2013). Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics. 23(1). 226–238. 83 indexed citations
2.
Thompson, John F., Seng-Jaw Soong, Charles M. Balch, et al.. (2011). Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database. Journal of Clinical Oncology. 29(16). 2199–2205. 250 indexed citations
3.
Balch, Charles M., Jeffrey E. Gershenwald, Seng-Jaw Soong, et al.. (2010). Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases. Journal of Clinical Oncology. 28(14). 2452–2459. 287 indexed citations
4.
Balch, Charles M., Jeffrey E. Gershenwald, Seng-Jaw Soong, et al.. (2009). Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology. 27(36). 6199–6206. 3342 indexed citations breakdown →
5.
Tanemura, Atsushi, Alicia M. Terando, Myung‐Shin Sim, et al.. (2009). CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma. Clinical Cancer Research. 15(5). 1801–1807. 157 indexed citations
6.
Faries, Mark B., Eddy C. Hsueh, Xing Ye, Mary T. Hoban, & Donald L. Morton. (2009). Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine. Clinical Cancer Research. 15(22). 7029–7035. 75 indexed citations
7.
Goto, Yasufumi, Takaaki Arigami, Minoru Kitago, et al.. (2008). Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Molecular Cancer Therapeutics. 7(11). 3642–3653. 93 indexed citations
8.
Amersi, Farin, Alicia M. Terando, Yasufumi Goto, et al.. (2008). Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. Clinical Cancer Research. 14(3). 638–645. 114 indexed citations
9.
Faries, Mark B., Richard Essner, Leland J. Foshag, et al.. (2006). Low lymph flow decreases with age and correlates with non-sentinel node metastases and poor survival in stage III melanoma. Cancer Research. 66. 1119–1119. 1 indexed citations
10.
Ravindranath, Mepur H., Eddy C. Hsueh, Meena Verma, Ye Wei, & Donald L. Morton. (2003). Serum Total Ganglioside Level Correlates With Clinical Course in Melanoma Patients After Immunotherapy With Therapeutic Cancer Vaccine. Journal of Immunotherapy. 26(3). 277–285. 13 indexed citations
11.
Balch, Charles M., Antônio C. Buzaid, Seng‐Jaw Soong, et al.. (2003). New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. Seminars in Surgical Oncology. 21(1). 43–52. 93 indexed citations
12.
13.
Haigh, Philip I., et al.. (1999). Long-Term Survival After Complete Resection of Melanoma Metastatic to the Adrenal Gland. Annals of Surgical Oncology. 6(7). 633–639. 53 indexed citations
14.
Morton, Donald L.. (1984). Xeroradiography of the Breast. Annals of Surgery. 199(4). 485. 6 indexed citations
15.
16.
Giuliano, Armando E., Reiko F. Irie, & Donald L. Morton. (1979). Rheumatoid factor in melanoma patients:Alterations of humoral tumor immunity in vitro. Cancer. 43(5). 1624–1629. 9 indexed citations
17.
Gupta, Rishab K., Hulbert K. B. Silver, Ralph A. Reisfeld, & Donald L. Morton. (1979). Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 39(5). 1683–95. 14 indexed citations
18.
Townsend, Courtney M., et al.. (1977). A new in vivo assay of human lymphocyte-mediated immunity to melanoma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 81(3). 345–50. 3 indexed citations
19.
Wile, Alan G., Frank C. Sparks, & Donald L. Morton. (1977). Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.. PubMed. 37(7 Pt 1). 2251–6. 11 indexed citations
20.
Gupta, Rishab K. & Donald L. Morton. (1975). Suggestive evidence for in vivo binding of specific antitumor antibodies of human melanomas.. PubMed. 35(1). 58–62. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martín C. Mihm Breakdown of academic impact, for papers by Merrick I. Ross Breakdown of academic impact, for papers by Alexander M.M. Eggermont Breakdown of academic impact, for papers by John M. Kirkwood Breakdown of academic impact, for papers by Claus Garbe Breakdown of academic impact, for papers by Richard A. Scolyer Breakdown of academic impact, for papers by Dirk Schadendorf Breakdown of academic impact, for papers by Kelly M. McMasters Breakdown of academic impact, for papers by Jeffrey E. Gershenwald Breakdown of academic impact, for papers by Daniel D. Von Hoff
Rankless by CCL
2026